Pruritus Therapeutics Market: By Disease Type (Atopic Dermatitis/Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-cell, and Others), By Product (Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, and Others), By Route of Administration (Oral, Parenteral, and Topical), and Geography

Pruritus Therapeutics Market size was valued at USD 9,735.6 Million in 2023 and is expected to grow at a CAGR of 5.0% from 2024 to 2030. The pruritus therapeutics market refers to the industry involved in developing and selling treatments for pruritus, which is a medical term for itching. Pruritus can be caused by various conditions such as dermatological disorders, systemic diseases, medications, or psychological factors. The market for pruritus therapeutics includes pharmaceuticals (both prescription and over-the-counter), and treatments aimed at alleviating itching and addressing underlying causes. During the projected period, the pruritus treatment market is expected to grow steadily. This growth will be driven by a rising global prevalence of pruritus cases, increased investment in healthcare infrastructure development, and government initiatives providing funding to research institutes and pharmaceutical companies for the development of new drugs and therapies.

Furthermore, major market players are making significant investments in research and development to discover new medications for chronic pruritus. Additionally, these companies are prioritizing the introduction of innovative drugs and building robust pipelines, which is expected to drive market growth. Moreover, the global market for chronic pruritus therapies is anticipated to expand during the forecast period due to increased mergers, collaborations, and acquisitions among industry participants. However, some key restraints of the pruritus therapeutics market include regulatory challenges in drug approval processes, limited awareness and diagnosis of underlying causes of pruritus among patients and healthcare providers, and the high cost associated with developing and accessing advanced therapies, which may hinder market growth.

Pruritus Therapeutics Market Key Developments:

• In June 2023, Ipsen stated that Bylvay has received approval from the United States Food and Drug Administration (FDA) for the treatment of cholestatic pruritus in patients with Alagille syndrome starting at the age of 12 months. Bylvay is an ileal bile acid transport inhibitor (IBATi) that operates locally in the small intestine and has very little systemic exposure. In the United States and for the treatment of progressive familial intrahepatic cholestasis (PFIC) in Europe, Bylvay was authorized as the first medication therapy option in 2021 for individuals suffering from cholestatic pruritus caused by PFIC. For qualified ALGS patients, Bylvay is instantly available by prescription.
• In August 2023, VeopozTM, also known as CD55-deficient protein-losing enteropathy, was authorized by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, according to Regeneron Pharmaceuticals, Inc. The first and only remedy suggested especially for CHAPLE is Veopoz. The pre-approval inspection concerns about the aflibercept 8 mg BLA have been resolved with the consent of Veopoz. In the next weeks, FDA action on the aflibercept 8 mg BLA is anticipated.